PERTUZUMAB PLUS TRASTUZUMAB FIXED DOSE COMBINATION

摘要

The application disclosed concerns a fixed dose combination (FDC) of pertuzumab, trastuzumab, and, optionally, recombinant human hyaluronidase (rHuPH20), which is administered subcutaneously to patients. The final efficacy and safety data for the FeDeriCa clinical trial, United States Prescribing Information (USPI) (including home- use) methods, and primary analysis of the PHranceSCa clinical trial are disclosed and claimed.